



DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HPTLC METHOD FOR SIMULTANEOUS ESTIMATION OF AMBROXOL HYDROCHLORIDE AND LORATADINE IN PHARMACEUTICAL DOSAGE FORM

¹ Samadhan Magar, ²Dr. Kailas Biyani

¹Research Scholar, ²Supervisor

^{1,2} School of Pharmacy, SunRise University, Alwar, Rajasthan, India

ABSTRACT:

Ambroxol Hydrochloride in combination with Loratadine is used in the treatment of cough. Stability indicating HPTLC method has been developed for simultaneous estimation of AMB and LORA. AMB and LORA were separated on silica gel 60 F₂₅₄ TLC plate using *Chloroform: Methanol (9:1 v/v)* as mobile phase. Chamber saturation time was 15 min. The optimum wavelength for detection and quantitation used was 216 nm. Both drugs were separated well from each other with R_f values 0.36±0.003 for AMB and 0.68±0.002 for LORA. Linearity for AMB and LORA was observed in the range of 600-3600ng/ band and 50-300ng/band respectively. The correlation of coefficient value nearer to 1 also indicates linearity of the method. The method was applied to marketed tablet formulation and the % amount of drug estimated was in good relationship with label claim. The method was validated as per ICH guidelines for linearity, accuracy, precision, and robustness. The accuracy of method was studied by recovery studies at 80%, 100 % and 120 %. The proposed method when used for re-estimation of AMB and LORA from its pharmaceutical formulation after over spotting with 80 %, 100 % and 120 % of additional drug showed good drug recovery in the range of 99.93 % to 100.01 % for AMB and 99.61 % to 100.86 % for LORA (% RSD less than 2) indicates accuracy of method. The precision of the method was expressed as %RSD and observed within limit indicate method is precise. The low value of LOD and LOQ indicates sensitivity of the method. The method robustness was studied by alteration in chromatographic conditions and results were concluded in terms of % RSD and found within acceptable limit for each parameter which express method is robust.

INTRODUCTION:

The purpose of stability testing is to provide evidence on how the quality of Drug substance or Drug Product varies with time under the influence of a variety of environmental factors such as temperature, humidity, and light, and to institute a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions. Stress testing studies are conducted to challenge the specificity of stability-indicating methods as part of validation protocol.

To develop and validation of stability-indicating methodology, to determination of degradation pathways of drug substances and drug products, to discernment of degradation product in formulations that are related to drug substances versus those that are related to non-drug substances (e.g., excipients), Structure elucidation of degradation products, to determine of the inherent stability of a drug substance in solution and solid state and to reveal the thermolytic, hydrolytic, oxidative, and photolytic degradation mechanism of the drug substance

and drug product.

In a quest to make drugs available for ever increasing diseases, disorders and ailments, new drugs, drug combinations and formulations are being introduced on regular interval. It is the responsibility and duty of analytical chemist to develop and validate analytical methods for these drugs, drug combinations and formulations.

Aim of the current work is to develop and validate quantitative analytical methods for active pharmaceutical ingredients (API) that are competent to meet up the requirements to be entitled as 'stability indicating method'. The developed method must be proficient for resolving potential interferents specifically degradation products which are formed during stability evaluation period. The extent of degradation of API under stress conditions will be studied.

Extensive literature survey with respect to 'Stability-indicating analytical methods' revealed that stability indicating methods for selected drugs or drug combinations as bulk and/or pharmaceutical formulations are not reported.

Materials and Methods

Materials:

Ambroxol hydrochloride obtained from Amilife sciences Pvt. Ltd. Baroda, Gujarat, India. Loratadine was obtained from Vasudha Pharmachem Ltd. Hyderabad, Telangana, India and all chemicals and reagents were purchased from S. D. Finechem, Mumbai and are of analytical grade.

Methods:

Solvent

As AMB and LORA both are soluble in methanol, methanol was selected as a solvent.

Instrumentation

HPTLC	Make/Specification
System	A Camag TL C system (Muttens, Switzerland)
Sample Applicator	Camag Linomat 5 sample applicator
Densitometry Scanner	Camag TLC Scanner
Data Processor	Camagwin CATS software (Version 1.4.2)
Development Chamber	Camag twin troughs (20 x 10 cm; 10 cm x 10 cm)
Syringe	Hamilton syringe (100 µl)
Slit Dimension	Set at 6 mm
Weighing Balance	ANAMED AA-2200
UV-Chamber	Camag UV-Cabinet

Selection of Detection Wavelength

Stock solutions (10 µg/ml) of drugs were prepared in methanol and their isobestic point is observed at 216 nm on UV-spectrophotometer shown in **Fig.1**

Preparation of Standard stock solution



Standard stock solution of LORA was prepared by dissolving 5 mg of drug in 10ml of methanol to get concentration of 500 µg/ml from which 1 ml was further diluted with methanol to get the final concentration 50ng/µl.

Standard stock solution of AMB was prepared by dissolving 60 mg of drug in 10ml of methanol to get concentration of 6000 µg/ml from which 1 ml was further diluted with methanol to get the final concentration 600ng/µl.

Selection of mobile phase and chromatographic conditions

Chromatographic separation studies were carried out on the working standard solution of LORA(10µg/ml)andAMB(10µg/ml).Initially,differentsolventslikeToluene,Methanol,EthylAcetateandBenzeneindifferentproportionsweretried.Finally the combination **Chloroform: Methanol (9:1 v/v)** offered good resolution. This mobile phase system was observed to give compact spots for both AMA and LORA and the R_f values were **0.36±0.003 and 0.68±0.002** for AMB and LORA respectively as showed in **Fig.2**. The chamber saturation time for mobile phase was 15 min and activation of plate was done at 110°C for five min to obtain distinct spots.

Analysis of Tablet formulation

Twenty tablets were weighed accurately and finely powdered. A quantity of powder equivalent to 5 mg of LORA and 60 mg of AMB was weighed and transferred to a 10 ml volumetric flask containing approximately 5 ml methanol. The mixture was sonicated for 5 min and then the solution was made to the mark with same solvent. The solution was filtered using Whatman paper no. 41. One millilitre of the above solution was further diluted with methanol to obtain the concentration 50 ng/band for LORA and 600 ng/band for AMB. Two microliter volume of this solution was applied on TLC plate to furnish concentration 100ng/band for LORA and 1200ng/band for AMB. After chromatographic development the peak areas of the bands were measured. The same analytical procedure was repeated for six times. AMB and LORA produced distinct peak at R_f 0.35 ± 0.003, 0.67 ± 0.002 respectively when scanning was done at 216 nm. The results are given in **Table. 1**. The result also shows that there is no interference between the drug and the excipients presents in tablet formulation.

Validation of Analytical

Method¹Linearity

Calibration was done by automatic sample applicator Linomat 5 on TLC plate to give concentration 600, 1200, 1800, 2400, 3000, 3600 ng/band of AMB and 50, 100, 150, 200, 250, 300 ng/band of LORA. The plates were developed in mobile phase. The graph for calibration was plotted as peak areas versus concentrations. The results are shown in **Table. 2** and Calibration curve in **Fig. 3. and Fig.4**.

Precision

The precision study was performed by intra-day and inter-day variation study. In the intraday study, three replicates of three different concentrations of AMB (1800, 2400, 3000 ng/band) and of LORA (150, 200, 250 ng/band) were analyzed in a day and percentage RSD was calculated. The % RSD was found to be in the range of 0.27-0.66 for AMB and 0.84-1.24 for LORA. For the inter day variation study, three

replicates of three different concentrations were analyzed on three consecutive days and percentage RSD was calculated. The % RSD was found to be in the range of 0.45-0.65 for AMB and 0.44-1.02 for LORA. The results are shown in **Table.3**

Accuracy

The consistency and accuracy of technique was ensured by recovery study. This study was carried out by spotting a mixture of standard drug solution to pre-analyzed sample solution at three different levels 80, 100 and 120 %. Basic concentration of sample chosen was 1200 ng/band for AMB and 100 ng/band for LORA. The experiment was carried out in triplicate. Results are depicted in **Table.4**.

Limit of Detection (LOD)

LOD is calculated from the formula:-

$$\text{LOD} = \frac{3.3 \times \sigma}{S}$$

Where,

σ = standard deviation of response for the lowest concentration in the range

S = slope of the calibration curve.

The results of LOD and LOQ are given in **Table. 5**.

Specificity

Specificity of the developed method was ascertained by analyzing standard AMB and LORA and AMB and LORA extracted from tablets. The band for AMB and Lora in the sample was confirmed by comparing the R_f and spectra of the band with those obtained from the standard. The Spectra is shown in **Fig. 5** and **Fig. 6**.

Robustness

As per the ICH, method robustness expresses its capacity to remain unaltered through small, deliberate variations in parameters of method. The parameters altered were change in mobile phase composition ($\pm 1\%$) and chamber saturation time ($\square 2$ min). The effects on result are observed by applying 3600 ng/band for AMB and 300 ng/band for LORA. Results are shown in **Table. 6**.

Forced degradation studies²⁻⁸

Forced degradation studies were carried under condition of acid, base, neutral hydrolysis, oxidation, photolytic and dry heat in order to evaluate the ability of the proposed method to separate both the drugs from their degradation products. Dry heat and photo degradation study was carried out in solid state. The results are shown in **Table .7**

Acid degradation

From the standard solution of AMB (6000 $\mu\text{g/ml}$) 1 ml solution was mixed with 1 ml of 0.1N HCl and 8 ml of methanol. The solution was refluxed at 60°C for 4 hrs. 3 μl volume was applied on TLC plate to get concentration 1800 ng/band.

Similarly from the standard stock solution of LORA (500 µg/ml) 1ml solution was mixed with 1ml of 0.1N HCl and 8 ml of methanol. The solution was refluxed at 60°C for 4 hrs. 3µl volume was applied on TLC plate to get concentration 150 ng/band. After acid treatment, 12.53 % of degradation was observed for AMB with additional products at R_f 0.48 and 0.52 and 11.78 % degradation was observed for LORA without appearance of degradation products shown in **Fig.7** and **Fig. 8**.

Alkaline degradation

From the standard solution of AMB (6000 µg/ml) 1 ml solution was mixed with 1ml of 0.1N NaOH and 8 ml of methanol. The solution was refluxed at 60°C for 4 hrs. 3µl volume was applied on TLC plate to get concentration 1800 ng/band.

Similarly from the standard stock solution of LORA (500µg/ml) 1ml solution was mixed with 1ml of 0.1N NaOH and 8 ml of methanol. The solution was refluxed at 60°C for 4 hrs. 3µl volume was applied on TLC plate to get concentration 150ng/band. After alkali treatment, 10.9% of AMB was found to undergo degradation with additional degradation product at R_f 0.45 and 7.56% degradation was observed for LORA without additional degradation product shown in **Fig.9** and **Fig. 10**.

Neutral Hydrolytic Degradation

From the standard solution of AMB (6000 µg/ml) 1 ml solution was mixed with 1ml of water and 8 ml of methanol. The solution was refluxed at 60°C for 4 hrs. 3µl volume was applied on TLC plate to get concentration 1800 ng/band.

Similarly from the standard stock solution of LORA (500µg/ml) 1ml solution was mixed with 1ml of water and 8 ml of methanol. The solution was refluxed at 60°C for 4hrs. 3 µl volume was applied on TLC plate to get concentration 150ng/band. On neutral hydrolysis, 18.82% degradation was observed for AMB with peak of degradation at R_f 0.19 and 0.24 and 15.70% of degradation was observed for LORA with peak of degradation at R_f 0.58 shown in **Fig.11** and **Fig. 12**.

Oxidative degradation

From the standard solution of AMB (6000 µg/ml) 1 ml solution was mixed with 1ml of 3% solution of H₂O₂ and 8 ml of methanol. The solution was refluxed at 60°C for 4hrs. 3 µl volume was applied on TLC plate to get concentration 1800ng/band.

Similarly from the standard stock solution of LORA (500µg/ml) 1ml solution was mixed with 1 ml of 3% solution of H₂O₂ and 8 ml of methanol. The solution was refluxed at 60°C for 4hrs. 3µl volume was applied on TLC plate to get concentration 150ng/band. In the oxidative condition, 9.07% degradation was observed for AMB with no peak of degradation and 19.22 % of degradation was observed for LORA with peak of degradation at R_f 0.61 shown in **Fig.13** and **Fig. 14**.

Degradation under dry heat

Dry heat studies were performed by keeping drug samples separately in oven (80°C) for a period of 2 hours. Samples were withdrawn after 2 hr, dissolved in methanol and diluted appropriately to get concentration of 600 µg/ml for AMB and 50 µg/ml for LORA. 3 µl volume was applied on TLC plate to get concentration 1800 ng/band for AMB and 150 ng/band for LORA. Under dry heat degradation condition, AMB showed 8.87% of degradation with additional product at R_f 0.40 and 18.39% LORA was found to be degraded with peak of degradation at R_f values 0.78 shown in **Fig. 15** and **Fig. 16**.

Photo-degradation studies

Photolytic study was carried out by exposure of drug individually to UV light upto 200 watt hours/square meter for period of 4 hrs. Sample was weighed, dissolved and diluted to get 1800 ng/band and 150 ng/band concentration for AMB and LORA resp. After exposing to light, 11.02% of AMB was found to be degraded with additional peak of degradation at R_f 0.48 and 9.57% of LORA was found to be degraded with peak of degradation at R_f 0.80 shown in **Fig. 17** and **Fig. 18**.





Fig. 1. Overlain UV Spectra of AMB and LORA






Fig. 3. Calibration curve of Ambroxol Hydrochloride




Fig. 4. Calibration curve of Loratadine




Fig. 5. Densitogram of Sample (AMB of 1200 ng/band, $R_f = 0.35 \pm 0.003$ and LORA of 100ng/band, $R_f=0.67 \pm 0.002$)

DISCUSSION:

Ambroxol Hydrochloride in combination with Loratadine is used in estimation of AMB and LORA. AMB and LORA were separated on silica gel 60 F₂₅₄ TLC plate using *Chloroform: Methanol (9:1 v/v)* as mobile phase. Chamber saturation time was 15 min. The optimum wavelength for detection and quantitation used was 216 nm. Both drugs were separated well from each other with R_f values **0.36 ± 0.003** for AMB and **0.68 ± 0.002** for LORA. Linearity for AMB and LORA was observed in the range of 600-3600 ng/band and 50-300 ng/band respectively. The correlation coefficient value nearer to 1 also indicates linearity of the method. The method was applied to marketed tablet formulation and the % amount of drug estimated was in good relationship with label claim. The method was validated as per ICH guidelines for Linearity, accuracy, precision, and robustness. The accuracy of method was studied by recovery studies at 80%, 100% and 120%. The proposed method when used for estimation of AMB and LORA from its pharmaceutical formulation after over spotting with 80%, 100% and 120% of additional drug showed good drug recovery in the range of **99.93% to 100.01% for AMB and 99.61% to 100.86% for LORA** (% RSD less than 2) indicates accuracy of method. The precision of the method was expressed as %RSD and observed within limit indicate method is precise. The low value of LOD and LOQ indicates sensitivity of the method. The method robustness was studied by alteration in chromatographic conditions and results were concluded in terms of % RSD and found within acceptable limit for each parameter which express method is robust. Method.

Conclusion:

AMB and LORA were exposed to various stress degradation conditions. Peaks obtained from the samples degraded by acid, alkali, water, hydrogen peroxide, dry heat and Photo treatment showed well separated spots of pure drugs and few degradation products spots at various R_f values. AMB showed degradation product peak under acid (**0.48, 0.52**), alkali (**0.45**), neutral (**0.19, 0.24**), dry heat (**0.40**) and Photo (**0.48**) conditions but did not show any observable peak in oxidation condition. LORA showed degradants peaks for neutral (**0.58**), oxidation (**0.61**), dry heat (**0.78**) and Photo (**0.80**) condition but did not show any observable peak in acid and alkali stress condition. The degradation peaks developed under various stress conditions for both AMB and LORA were well separated from the peak of the intact drugs. The peaks of the AMB and LORA were not remarkably shifted in the presence of the degradation peaks, which specify the stability-indicating character of the developed method.



REFERENCE:

1. Pai PNS, Rou G.K., Lalitha N. Spectrophotometric determination of Ambroxol Hydrochloride. *Ind. Journal Pharma. Sci*; 67(02), 2006, 741-742.
2. Ilangoan P., Cheorolu S.N., Asha P., Simultaneous estimation of Ambroxol Hydrochloride and Loratadine in tablet dosage form by using UV Spectrophotometric method, *Int.J.Pharm.Bio.Sci*, Vol2,2,2011,338-344 .
3. E.A. Sharma and N.J Shah, Development and validation of dual wavelength UV Spectrophotometric method for simultaneous estimation of Ambroxol Hydrochloride and Loratadine Hydrochloride in their combined tablet dosage form, *IJPSR*; 3 (8), 2012, 2584-2589.
4. M.M. Mabrouk, H.M. El-Fatary a , Sherin Hammad a , Abdel Aziz M. Wahbi, Simultaneous estimation of Loratadine and Pseudoephedrine sulphate in pharmaceutical formulations by RP-HPLC and derivative Spectrophotometry ,*Journal of Pharmaceuticals and Bio medical analysis*, 33, 2003, 597- 604.
5. Abol Hassan Ahmadiani, Rapid determination of Loratadine in small volume samples by HPLC with fluorescence detection, *Journal of chromatography B*, 809, 2004, 227- 230.
6. Vemula V.B., HPLC method development and validation for simultaneous estimation of Sulfasalazine and Pyrimethamine in tablet dosage form. *Int.J.Pharm. Sci.* 3(4), 2013, 295-298.
7. Powel K.K., Determination of Loratadine in human plasma by HPLC method with UV detection. *Journal of Chromatography B*, 755, 2001, 331-335.
8. Prince Francis Moses, Prathap Singh, Alagar Raja, David Banji, Analytical method development and validation for simultaneous estimation of Ambroxol Hydrochloride and Desloratadine in its pharmaceuticals dosage form by RPHPLC, *WJPPS*, Volume 2(6), 2013, 6246-6262.
9. ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology, Q2 (R1) November 2005, 1-17.
10. Tripathi, K.D. *Essential of Medical Pharmacology*, 5th ed.; Jaypee Brother Medical Publisher (P) LTD: New Delhi, 2004; pp 210, 407.
11. Donald, J.A. *Medicinal Chemistry Drug Discovery*, 6th ed.; a john willy and sons inc: New Delhi, 2007; pp 234-250.
12. Thomas, L.L., David, A.W., Victoria, F.R., William, S. *Principle of Medicinal Chemistry*, 6th ed.; Wolter Kluwer (india) Pvt. Ltd: New Delhi, 2008; pp 156-160.



13. Brunton, L.L.; Lazo, S.J.; Parker, L.K. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 11th ed.; McGraw-hill, 2006; pp 582-583.
14. Rang, H.P.; Dale, M.M.; Ritter, J.M.; Moore, P.K. Pharmacology, 5th ed.; Churchill Livingstone, 2007; pp 253- 255.
15. Block, H.B.; Beale, M.J. Wilson and Griswold's Text Book of Organic an Pharmaceutical Chemistry, Lippincott Williams and Wilkines , 11th ed.; 2001; pp 872-877.
16. ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures:Text and Methodology Q2 (R1) 8. Wikipedia---<https://en.wikipedia.org/wiki/Ambroxol> and <https://en.wikipedia.org/wiki/Loratadine>

